On June 4-8, Eastern Time, the 57th American Society of Clinical   Oncology (ASCO) Annual Meeting in 2021 was held in the form of an online   conference. The research result on small cell lung cancer (SCLC) by Kong   Tiandong, a master’s tutor of clinical medicine in HENU, a young scholar of   Cancer Hospital of Zhengzhou (The Third People's Hospital of Zhengzhou), and Director   of the Department of Respiratory Oncology was accepted by the conference, and   he communicated with participating experts for exchanges in the form of a   poster, which demonstrated the innovative strength of HENU in the field of   clinical oncology research on the international stage. This result is   expected to be included in abstract form by the top journal JCO (Journal of   Clinical Oncology) (IF=32.9). This is also another embark of the results of   the deputy chief physician Kong Tiandong's team on the international clinical   oncology scientific research stage after the European Society for Medical Oncology   (ESMO) Congress 2020.

ASCO Annual Meeting is the world’s largest, highest academic and   most authoritative clinical oncology conference, bringing together many   world-class oncologists to share and discuss the current international   cutting-edge clinical oncology research results and tumor treatment   technologies. Many important research findings and clinical trial results   will be released for the first time at the ASCO Annual Meeting.

The American Society of Clinical Oncology (ASCO) was established   in 1964 and is the world's leading academic organization for oncology. It   brings together more than 25,000 professionals from a wide range of fields.   The annual meeting is characterized by the presentation of the latest results   of basic and clinical cancer research. Many important research findings and   clinical trial results that year were released at the ASCO Annual Meeting. As   the world's largest and the most authoritative clinical oncology conference   with the highest academic level, ASCO Annual Meeting has always been the most   important international academic event for oncology experts and scholars   worldwide, and it also demonstrates the research directions in the field of   oncology.

SCLC is a tumor which is highly aggressive, rapidly progressing and   prone to widely spread. Although it only accounts for 13-15% of all lung   cancers, it is highly malignant and most patients have a poor prognosis. SCLC   is relatively sensitive to radiotherapy and chemotherapy, but it is extremely   drug resistant. Even the combination with PD-L1 monoclonal antibody and   chemotherapy, it still is limited in the improvement of survival. Therefore,   improving the treatment of SCLC has always been a thorny issue in the clinic   medicine. The scientific research achievements of Professor Kong Tiandong, a   young scholar of HENU, which appeared on the international academic stage   this time, extended the median overall survival of the first-line treatment   of SCLC to 15 months, which was recognized by international colleagues.